News Releases

News Releases

Date Title
Nov 07, 2019 Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 10, 2019 UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
Oct 02, 2019 Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
Sep 18, 2019 Ra Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General
Sep 04, 2019 Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis
Aug 21, 2019 Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck
Aug 07, 2019 Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 26, 2019 Ra Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jul 23, 2019 Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Jul 22, 2019 Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Jul 16, 2019 Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan
Jun 04, 2019 Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy
May 28, 2019 Ra Pharmaceuticals to Present at Upcoming Investor Conferences
May 14, 2019 Ra Pharmaceuticals to Present at Upcoming Investor Conferences
May 09, 2019 Ra Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 07, 2019 Ra Pharmaceuticals Announces Positive gMG Phase 2 and Open-Label, Long-Term Extension Data at the 2019 AAN Annual Meeting
Apr 24, 2019 Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress
Apr 09, 2019 Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study
Apr 01, 2019 Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting
Mar 07, 2019 Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Mar 04, 2019 Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
Feb 28, 2019 Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Feb 21, 2019 Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference